• Asian Pacific Journal of Cancer Prevention
• /
• 제16권15호
• /
• pp.6627-6632
• /
• 2015

Background: We conducted a study exploring the clinical safety and efficacy of decitabine in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), combined with a complex karyotype. Materials and Methods: From April 2009 to September 2013, a total of 35 patients with AML/MDS combined with a complex karyotype diagnosed in the First Affiliated Hospital of Soochow University were included for retrospective analysis. All patients were treated with decitabine alone ($20mg/m^2$ daily for 5 days) or combination AAG chemotherapy (Acla 20mg qod*4d, Ara-C $10mg/m^2$ q12h*7d, G-CSF $300{\mu}g$ qd, the dose of G-CSF adjusted to the amount in blood routinely). Results: In 35 patients, 15 exhibited a complete response (CR), and 6 a partial response (PR), the overall response rate (CR+PR) being 60% (21 of 35). Median disease-free survival was 18 months and overall survival was 14 months. In the 15 MDS patients with a complex karyotype, the CR rate was 53.3% (8 of 15); in 20 AML patients with complex karyotype, the overall response rate was 65% (13 of 20). The response rate of decitabine alone (22 cases) was 56.5% (13 of 22), while in the combination chemotherapy group (13 cases), the effective rate was 61.5% (8 of 13)(P>0.05). There are 15 patients with chromosome 7 aberration, after treatment with decitabine, 7 CR, 3 PR, overall response rate was 66.7% (10 of 15). Of 18 patients with 3 to 5 kinds of chromosomal abnormalities, 66.7% demonstrated a response; of 17 with more than 5 chromosomal abnormalities, 52.9% had a response. In the total of 35 patients, with one course (23 patients) and ${\geq}$two courses (12 patients), the overall response rate was 40.9% and 92.3% (P<0.05). Grade III to IV hematological toxicity was observed in 27 cases (75%). Grade III to IV infections were clinically documented in 7 (20%). Grades I to II non-hematological toxicity were infections (18 patients), haematuria (2 patients), and bleeding (3 patients). With follow-up until September 2013, 7 patients were surviving, 18 had died and 10 were lost to follow-up. In the 6 cases who underwent allogeneic hematopoietic stem cell transplantation (HSCT) all were still relapse-free survivors. Conclusions: Decitabine alone or combination with AAG can improve outcome of AML/MDS with a complex karyotype, there being no significant difference decitabine in inducing remission rates in patients with different karyotype. Increasing the number of courses can improve efficiency. This approach with fewer treatment side effects in patients with a better tolerance should be employed in order to create an improved subsequent chance for HSCT.

• Journal of Radiation Protection and Research
• /
• 제18권2호
• /
• pp.1-16
• /
• 1993

급성 전신 및 부분 피폭시 피해자들에 대한 치료방침의 결정에 있어 참고자료로서 사용하기 위하여 저자들은 체외에서 말초혈액을 ${60}Co\;{\gamma}-$선으로 2Gy에서 12Gy까지 방사선 조사하여 말초 임파구에서 관찰되는 염색체이상의 빈도와 방사선량과의 관계를 실험적으로 연구하였다. 관찰된 세포중 불안정 염색체이상(dicentric 염색체, ring 염색체, acentric fragment쌍)이 나타난 세포의 비율은 2Gy에서 32%, 4Gy에서 47%, 6Gy에서 80%, 8Gy에서 94%, 10Gy이상에서는 100%였다. 급성 전신 피폭시 평균 흡수선량을 반영하는 지표인 Ydr은 2Gy에서 0.373, 4Gy에서 0.669, 6Gy에서 1.734, 8Gy에서 2.773, 10Gy에서 3.746 그리고 12Gy에서 5.454였다. 방사선량(D)과 염색체이상(dicentric염색체와 ring염색체의 합) 빈도(Ydr)와의 관계는 $Ydr=9.322{\times}10^{-2}/Gy{\times}D+2.975{\times}10^{-2}/Gy^2{\times}D^2$로 나타났다. 신체의 부분피폭시의 선량 및 과거의 피폭선량을 계산할 때 사용하는 지표인 Qdr은 2Gy에서 1.166, 4Gy에서 1.436, 6Gy에서 2.173, 8Gy에서 2.945, 10Gy에서 3.746, 그리고 12Gy에서 5.454였다. 이와 같은 선량측정방법의 신빙도를 검증하기 위하여 신체의 부분에 균일한 선량분포의 1.8Gy, 2.5Gy 및 7.0Gy의 방사선치료를 일회 받은 환자들로부터 구한 Qdr은 각각 1.109, 1.222, 2.222였으며 이로부터 $Qdr=Ydr/(1-e^{Ydr})$의 관계식을 이용하여 계산해 낸 피폭선량은 1.52Gy, 2.48Gy 및 6.54Gy로서 실제 조사한 선량과 매우 근사한 결과를 얻었다.